[en] In myeloid leukemia, immature leukemic cells are able to egress into peripheral blood to infiltrate extra-medullary organs. We therefore analyzed the migrating and invasive potential of human HL-60 and NB4 cell lines, representative of acute myelogenous leukemia, their ability to express matrix metalloproteases (MMPs), tissue inhibitors of metalloproteases (TIMPs) and urokinase plasminogen activator (uPA) in response to differentiating agents. Granulocytic differentiation by all-trans-retinoic acid (ATRA) and aclacinomycin (ACLA) strongly increased HL-60 and NB4 cell migration and invasion. At mRNA and protein levels, these cell lines produced significant amounts of MMP-9 (HL-60 < NB4). Granulocytic differentiation by ACLA increased both pro and active forms of MMP-9 whereas ATRA decreased them and stimulated uPA mRNAs. TIMP-1, the physiological MMP inhibitor, increased during granulocytic differentiation whereas TIMP-2 did not significantly vary. Use of Batimastat and aprotinin suggests that ATRA was active by modulating the uPA system while ACLA interfered with MMP expression. In conclusion, our data demonstrate that HL-60 and NB4 cells express MMPs and uPA which are differentially regulated by the differentiating agents ATRA and ACLA and suggest the clinical usefulness of MMPs and serine protease inhibitors in the prophylaxis and treatment of the ATRA syndrome. (C) 2002 Elsevier Science Inc. All rights reserved.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Devy, L.
Hollender, P.
Munaut, Carine ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Colige, Alain ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Protéines et glycoprot. de matr.extracell. et membran.basal.
Garnotel, R.
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique
Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Jeannesson, P.
Language :
English
Title :
Matrix and serine protease expression during leukemic cell differentiation induced by aclacinomycin and all-trans-retinoic acid
Petrides P.E., Dittman K.H. (1990) How do normal and leukemic white blood cells egress from the bone marrow? Morphological facts and biochemical riddles. Blut 61:21-23.
Bianchi E., Bender J.R., Blasi F., Pardi R. (1997) Through and beyond the wall: Late steps in leukocyte transendothelial migration. Immunol Today 12:586-591.
Noël A., Gilles C., Bajou K., Devy L., Kebers F., Lewalle J.M., Maquoi E., Munaut C., Remacle A., Foidart J.M. (1997) Emerging roles for proteases in cancer. Invasion Metastasis 17:221-239.
Ivanoff A., Ivanoff J., Hultenby K., Sundqvist K.G. (1999) Infiltrative capacity of T leukemia cell lines: A distinct functional property coupled to expression of matrix metalloprotease-9 (MMP-9) and tissue inhibitor metalloprotease-1 (TIMP-1). Clin Exp Metastasis 17:695-711.
Murphy G., Stanton H., Cowell S., Butler G., Knauper V., Atkinson S., Gavrilovic J. (1999) Mechanisms for pro matrix metalloprotease activation. APMIS 107:38-44.
Quaranta V. (2000) Cell migration through extracellular matrix: Membrane-type metalloproteases make the way. J Cell Biol 149:1167-1170.
Pei D. (1999) Leukolysin/MMP25/MT6-MMP: A novel matrix metalloprotease specifically expressed in the leukocyte lineage. Cell Res 9:291-303.
Liesveld J.L. (1997) Expression and function of adhesion receptors in acute myelogenous leukemia: Parrallels with normal erythroid and myeloid progenitors. Acta Haematol 97:53-62.
Jiang Y., Zhao R.C., Verfaillie C.M. (2000) Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc Natl Acad Sci USA 97:10538-10543.
Breitman T.R., Collins S.J., Keene B.R. (1981) Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 57:1000-1004.
Lanotte M., Martin-Thouvenin V., Najman S., Balerini P., Valensi F., Berger R. (1991) NB4, a maturation inducible cell line with t (15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77:1080-1086.
Botos I., Scappozza L., Zhang D. (1996) Batimastat, a potent matrix metalloprotease inhibitor, exhibits an unexpected mode of binding. Proc Natl Acad Sci USA 39:2749-2754.
Noël A., Calle A., Emonard H.P., Nusgens B.V., Simar L., Foidart J., Lapiere C.M., Foidart J.M. (1991) Invasion of reconstituted basement membrane matrix is not correlated to the malignant metastatic cell phenotype. Cancer Res 51:405-414.
Collins S.J., Ruscetti F.W., Gallagher R.E., Gallo R.C. (1978) Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci USA 75:2458-2462.
Morodomi T., Ogata Y., Sasaguri Y., Morimatsu M., Nagase H. (1992) Purification and characterization of matrix metalloprotease 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem J 285:603-611.
Collins S.J., Gallo R.C., Gallagher R.E. (1977) Continuous growth and differentiation of human myeloid leukemic cells in suspension culture. Nature 270:347-349.
Moll U.M., Youngleib G.L., Rosinski K.B., Quigley J.P. (1990) Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: Isolation and characterization of the enzyme from HT1080 tumor cells. Cancer Res 50:6162-6170.
Heussen C., Dowdle E.B. (1980) Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102:196-202.
Janiak M., Hashmi H.R., Janowska-Wieczoreck A. (1994) Use of the matrigel-based assay to measure the invasiveness of leukemic cells. Exp Hematol 22:559-565.
Mustjoki S., Alitalo R., Stephens R.W., Vaheri A. (1999) uPA plasminogen activation in human leukemia and in normal hematopoietic cells. APMIS 107:144-149.
Blasi F. (1999) Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the uPA-uPAR-PAI-1 system. Thromb Haemostasis 82:298-304.
Kossakowska A.E., Huchcroft S.A., Urbanski S.J., Edwards D.R. (1996) Comparative analysis of the expression patterns of metalloproteases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer 73:1401-1408.
Ries C., Loher F., Zang C., Ismair M.G., Petrides P.E. (1999) Matrix metalloprotease production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res 5:1115-1124.
Matsuzaki A., Janowska-Wieczorek A. (1997) Unstimulated human acute myelogenous leukemia blasts secrete matrix metalloproteases. J Cancer Res Clin Oncol 123:100-106.
Degos L., Dombret H., Chomienne C., Daniel M.T., Miclea J.M., Chastang C., Castaigne S., Fenaux P. (1995) All-trans-retinoic acid as a differentiation agent in the treatment of acute promyelocytic leukemia. Blood 85:2643-2653.
Ho P.T., Ishiguro K., Sartorelli A.C. (1989) Regulation of transferrin receptor in myeloid and monocytic differentiation of HL-60 leukemia cells. Cancer Res 49:1989-1995.
Hu Z.B., Ma W., Uphoff C.C., Lanotte M., Drexler H.G. (1993) Modulation of gene expression in the acute promyelocytic leukemia cell line NB4. Leukemia 7:1817-1823.
Chen A., Licht J.D., Wu Y., Hellinger N., Scher W., Waxman S. (1994) Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents. Blood 84:2122-2129.
Janowska-Wieczorek A., Marquez L.A., Matsuzaki A., Hashmi H.R., Larratt L.M., Boshkov L.M., Turner A.R., Zhang M.C., Edwards D.R., Kossakowska A.E. (1999) Expression of matrix metalloproteases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: Comparison with normal bone marrow cells. Br J Haematol 105:402-411.
Devy L., Noël A., Baramova E., Bajou K., Trentesaux C., Jardillier J.C., Foidart J.M., Jeannesson P. (1997) Production and activation of matrix-9 (MMP-9) by HL-60 promyelocytic leukemia cells. Biochem Biophys Res Commun 238:842-846.
Zang C., Liu H., Ries C., Ismair M.G., Petrides P.E. (2000) Enhanced migration of the acute promyelocytic leukemia cell line NB4 under in vitro conditions during short-term all-trans-retinoic acid treatment. J Cancer Res Clin Oncol 126:33-40.
Pyke C., Kristensen P., Ralfkiaer E., Grondahl-Hansen J., Eriksen J., Blasi F., Dano K. (1991) Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138:1059-1067.
Lehti K., Lohi J., Valtanen H., Keshi-Oja J. (1998) Proteolytic processing of membrane-type-1 matrix metalloprotease is associated with gelatinase A activation at the cell surface. Biochem J 334:345-353.
Nakada M., Nakamura H., Ikeda E., Fujimoto N., Yamashita J., Sato H., Seiki M., Okada Y. (1999) Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteases in human astrocytic tumors. Am J Pathol 154:417-428.
Okada A., Bellocq J.P., Rouyer N., Chenard M.P., Rio M.C., Chambon P., Basset P. (1995) Membrane-type matrix metalloprotease (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 92:2730-2734.
Lopez-Karpovitch X., Cardenas R., Piedras J. (1997) Immunophenotypic characteristics of the blast crisis in chronic myeloid leukemia. Rev Invest Clin 49:31-36.
Alving B.M., Krishnamurti C., Liu Y.P., Lucas D.L., Wright D.G. (1988) Stimulated production of urokinase and plasminogen activator inhibitor-2 by the human promyelocytic leukemia cell line HL-60. Thromb Res 51:175-185.
Mustjoki S., Tapiovaara H., Siren V., Vaheri A. (1998) Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells. Leukemia 12:164-174.
Tallman M.S., Anderson J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Ogden A., Shepherd L., Rowe J.M., Francois C., Larson R.S., Wiernik P.H. (2000) Clinical description of 44 patients with acute promyelocytic leukemia who developped the retinoic ATRA syndrome. Blood 95:90-95.
De Ridder M.C., Van der Plas A.J., Erpelinck-Verschueren C.A., Lowenberg B., Jansen J.H. (1999) Dexamethasone does not counteract the response of acute promyelocytic leukaemia cells to all-trans-retinoic acid. Br J Haematol 106:107-110.
Sham R.L., Phatak P.D., Belanger K.A., Packman C.H. (1996) The effect of dexamethasone on functional properties of HL60 cells during all-trans-retinoic acid induced differentiation. Are there implications for the retinoic acid syndrome?. Blood Cells Mol Dis 22:139-149.
Guedez L., Courtemanch L., Stetler-Stevenson M. (1998) Tissue inhibitor of metalloprotease (TIMP)-1 induces differentiation and an anti-apoptotic phenotype in germinal center B cells. Blood 92:1342-1349.
Blavier L., Henriet P., Imren S., Declerck Y.A. (1999) Tissue inhibitors of matrix metalloproteases in cancer. Ann NY Acad Sci 878:108-119.
